1. Furazosin
2. Hcl, Prazosin
3. Hydrochloride, Prazosin
4. Minipress
5. Pratsiol
6. Prazosin
7. Prazosin Hcl
1. 19237-84-4
2. Prazosin Hcl
3. Minipress
4. Vasoflex
5. Peripress
6. Furazosin Hydrochloride
7. Minipress Xl
8. Hypovase
9. 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine Hydrochloride
10. Cp-12299-1
11. Prazosin (hydrochloride)
12. 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine Monohydrochloride
13. Cp-12,299-1
14. Prazosinhydrochloride
15. (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(furan-2-yl)methanone Hydrochloride
16. [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone;hydrochloride
17. Mls000028454
18. Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, Monohydrochloride
19. Nsc-292810
20. X0z7454b90
21. Deprazolin
22. Hypovasole
23. Pratsiol
24. Sinetens
25. Smr000058384
26. Minipress (tn)
27. 19237-84-4 (hcl)
28. 2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline Hydrochloride
29. 2-{4-[(furan-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine Hydrochloride
30. Chebi:8365
31. Hsdb 3298
32. Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanyl-, Hydrochloride (1:1)
33. C19h21n5o4.hcl
34. Nsc 292810
35. Prazosin Clorhidrato [spanish]
36. Prazosine Hydrochloride
37. Sr-01000003052
38. Einecs 242-903-4
39. Mfcd00058177
40. Unii-x0z7454b90
41. Pressin And Hypovase
42. Prazosin Hydrochloride [usan:usp:jan]
43. Prazosin Hydrochloride;
44. Opera_id_370
45. Chembl1558
46. Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-, Monohydrochloride
47. Schembl41257
48. Mls001148201
49. Mls001333696
50. Mls002153280
51. Mls002222304
52. Spectrum1500495
53. Prazosin Hcl (furazosin Hcl)
54. Piperazin-1-yl)(furan-2-yl)
55. Hy-b0193a
56. Dtxsid50172822
57. Hms1570n16
58. Hms1920j10
59. Pharmakon1600-01500495
60. Prazosin Hydrochloride [mi]
61. Bcp13643
62. Prazosin Hydrochloride (jp17/usp)
63. Prazosin Hydrochloride [jan]
64. Tox21_501002
65. Ac-699
66. Ccg-39227
67. Nsc292810
68. Nsc757286
69. Prazosin Hydrochloride [hsdb]
70. Prazosin Hydrochloride [usan]
71. S1424
72. Prazosin Hydrochloride [vandf]
73. Akos015895394
74. Prazosin Hydrochloride [mart.]
75. Af-0012
76. H37p844
77. Lp01002
78. Nsc-757286
79. Prazosin Hydrochloride [usp-rs]
80. Prazosin Hydrochloride [who-dd]
81. Sb17352
82. Prazosin Hydrochloride, >=99% (tlc)
83. Quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-, Hydrochloride
84. Ncgc00094296-01
85. Ncgc00094296-02
86. Ncgc00094296-03
87. Ncgc00094296-04
88. Ncgc00094296-05
89. Ncgc00261687-01
90. Ba164294
91. Db-044795
92. Prazosin Hydrochloride [ep Impurity]
93. Prazosin Hydrochloride [orange Book]
94. Eu-0101002
95. P0938
96. Prazosin Hydrochloride [ep Monograph]
97. Prazosin Hydrochloride [usp Monograph]
98. D00609
99. H11453
100. Minizide Component Prazosin Hydrochloride
101. Prazosin Hydrochloride 100 Microg/ml In Methanol
102. Prazosin Hydrochloride Component Of Minizide
103. Sr-01000003052-2
104. Sr-01000003052-8
105. W-107719
106. Q27108060
107. Piperazine,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-, Monohydrochloride
108. Prazosin Hydrochloride, European Pharmacopoeia (ep) Reference Standard
109. Prazosin Hydrochloride, United States Pharmacopeia (usp) Reference Standard
110. 1-(4-amino-6,7-dimethoxy-2-quinazol Inyl)-4-(2-furanylcarbonyl)piperazine Hydrochloride
111. Piperazine,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, Monohydrochloride
| Molecular Weight | 419.9 g/mol |
|---|---|
| Molecular Formula | C19H22ClN5O4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 419.1360319 g/mol |
| Monoisotopic Mass | 419.1360319 g/mol |
| Topological Polar Surface Area | 107 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 544 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Prazosin hydrochloride |
| Drug Label | Prazosin hydrochloride, a quinazoline derivative, is the first of a new chemical class of antihypertensives. It is the hydrochloride salt of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl) piperazine and its structural formula is:Prazosin hydro... |
| Active Ingredient | Prazosin hydrochloride |
| Dosage Form | Capsule |
| Route | oral; Oral |
| Strength | eq 5mg base; eq 2mg base; eq 1mg base |
| Market Status | Prescription |
| Company | Ivax Sub Teva Pharms; Teva Pharms; Mylan |
| 2 of 2 | |
|---|---|
| Drug Name | Prazosin hydrochloride |
| Drug Label | Prazosin hydrochloride, a quinazoline derivative, is the first of a new chemical class of antihypertensives. It is the hydrochloride salt of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl) piperazine and its structural formula is:Prazosin hydro... |
| Active Ingredient | Prazosin hydrochloride |
| Dosage Form | Capsule |
| Route | oral; Oral |
| Strength | eq 5mg base; eq 2mg base; eq 1mg base |
| Market Status | Prescription |
| Company | Ivax Sub Teva Pharms; Teva Pharms; Mylan |
Adrenergic alpha-Antagonists; Antihypertensive Agents; Sympatholytics
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Prazosin hydrochloride is used in the management of hypertension. Prazosin's efficacy in hypertensive patients is similar to that of thiazide diuretics, beta-adrenergic blocking agents, hydralazine, and centrally acting adrenergic inhibitors (eg, clonidine, methyldopa). ... Prazosin has been shown to be effective in the management of hypertension in patients undergoing chronic hemodialysis, and the drug may be particularly useful in the acute management of severe hypertension in patients with increased concentrations of circulating catecholamines.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1860
Prazosin has been used with good results alone or in combination with a beta-adrenergic blocking agent for the preoperative management of the signs and symptoms of pheochromocytoma in a limited number of patients; however, these patients may be particularly susceptible to a marked hypotensive response to the initial dose of prazosin. Limited data also suggest that prazosin may be useful for the treatment of Raynaud's disease or phenomenon and ergotamine induced peripheral ischemia.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1861
Prazosin may be used as an adjunct to digoxin and diuretics for the treatment of congestive heart failure. However, prazosin has not been shown to improve survival in these patients. /NOT included in US product labeling/
MICROMEDEX Thomson Health Care. USPDI - Drug Information for the Health Care Professional. 22nd ed. Volume 1. MICROMEDEX Thomson Health Care, Greenwood Village, CO. 2002. Content Reviewed and Approved by the U.S. Pharmacopeial Convention, Inc., p. 2430
For more Therapeutic Uses (Complete) data for PRAZOSIN HYDROCHLORIDE (11 total), please visit the HSDB record page.
May cause syncope with sudden loss of consciousness, usually attributable to an excessive postural hypotensive effect; risk may be reduced by limiting the initial dose of the drug to 1 mg, and by subsequently increasing the dosage slowly. Adverse reactions include dizziness, drowsiness, and other CNS effects; patients should be cautioned regarding activities such as driving and operating machinery, as well as interactions with other CNS acting drugs including alcohol. Other adverse reactions include palpitations and nausea. The concurrent use of a beta-adrenergic blocking agent may increase the risk of hypotension. /Prazosin hydrochloride/
Hussar, D.A. (ed.). Modell's Drugs in Current Use and New Drugs. 38th ed. New York, NY: Springer Publishing Co., 1992., p. 135
When prazosin is used as a fixed-combination preparation that includes polythiazide, the cautions, precautions, and contraindications associated with thiazide diuretics must be considered in addition to those associated with prazosin.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1862
Caution should be used when adding prazosin to a preexisting antihypertensive regimen or when adding other hypotensive agents to a prazosin regimen in order to avoid a possible rapid fall in blood pressure. Caution should be used when administering prazosin to patients with chronic renal failure as they may require only small doses of the drug.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1862
Prazosin has been used alone or in combination with other hypotensive agents for the management of severe hypertension in a limited number of pregnant women without apparent adverse effect on the fetus. There are no adequate and well controlled studies to date using prazosin in pregnant women, however, and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1862
For more Drug Warnings (Complete) data for PRAZOSIN HYDROCHLORIDE (18 total), please visit the HSDB record page.
Adrenergic alpha-1 Receptor Antagonists
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
There is intraindividual and interindividual variation in the rate of absorption and plasma concentrations of prazosin. The absolute oral bioavailability of prazosin is also variable but is reported to average about 60% (range: 43-82%). Results of one study indicate that the presence of food may delay absorption of the drug in some patients, but does not affect the extent of absorption.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1863
Following oral administration of prazosin hydrochloride, plasma concentrations of the drug reach a peak in 2-3 hrs in most fasting patients. Plasma concentrations of prazosin generally do not correlate with therapeutic effect. One manufacturer reports that plasma concentrations of the drug after a single 5 mg dose range from 0.01-0.075 ug/ml. Blood pressure begins to decrease within 2 hr after an oral dose; the maximum decrease occurs in 2-4 hr. The hypotensive effect of prazosin lasts less than 24 hr.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1863
Animal studies indicate that prazosin is widely distributed in body tissues. After iv administration in dogs, highest concentrations of the drug are found in the lungs, coronary arteries, aorta, paw arteries and heart; the lowest concentrations are in the brain. During prazosin therapy, approximately 97% of the drug in plasma is bound to proteins. It is not known whether the drug crosses the placenta. Prazosin is distributed into milk in small amounts.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1863
Approximately 6-10% of a dose is excreted in urine and the remainder in feces via bile.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1863
The drug /prazosin hydrochloride/ is tightly bound to plasma proteins (primarily alpha1-acid glycoprotein), and only 5% of the drug is free in the circulation; diseases that modify the concentration of this protein (e.g., inflammatory processes) may change the free fraction. Prazosin is extensively metabolized in the liver, and little unchanged drug is excreted by the kidneys.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 246
Animal studies show that prazosin hydrochloride is metabolized extensively in the liver, principally by demethylation and conjugation, and excreted as unchanged drug (5-11%) and metabolites. Four of the metabolites have been shown to possess 10-25% of the hypotensive activity of prazosin and they may contribute to the antihypertensive effect of the drug.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1863
The 6-O-demethyl and 7-O-demethyl analogues of the new antihypertensive drug prazosin [2-[4-(2-furoyl)-piperazin-1-yl]-4-amino-6,7-dimethoxyquinazoline hydrochloride] have been unequivocally synthesized via separate 10-step reaction sequences starting from isovanillin and vanillin, respectively. The 6-O-demethyl derivative was found to be identical with the major prazosin metabolite formed in dog and rat, while the 7-O-demethyl derivative was identical with another, less prevalent but significant metabolite. Two minor metabolites of prazosin, 2-(1-piperazinyl)-4-amino-6,7-dimethoxyquinazoline and 2,4-diamino-6,7-dimethoxyquinazoline, are also described. All 4 metabolites are less potent blood pressure lowering agents in dogs than prazosin but may contribute to its antihypertensive effect, since they account for a major portion of the administered dose.
PMID:833813 Althius T, Hess H; J Med Chem 20 (1): 146-9 (1977)
Elimination half-life approx 3 hr.
Haddad, L.M., Clinical Management of Poisoning and Drug Overdose. 2nd ed. Philadelphia, PA: W.B. Saunders Co., 1990., p. 1348
The plasma half-life of prazosin after oral administration has been reported to be 2-4 hr.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1863
Animal studies indicate that prazosin does not have its antihypertensive effect in the CNS. Prazosin does not interfere with nerve impulse transmission across sympathetic ganglia nor does it cause adrenergic neuronal blockade.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2002 (Plus Supplements)., p. 1862
The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Animal studies have suggested that the vasodilator effect of prazosin is also related to blockade of postsynaptic alpha-adrenoceptors. The results of dog forelimb experiments demonstrate that that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional alpha- blockers, the antihypertensive action of prazosin is usually not accompanied by reflex tachycardia.
Medical Economics Co; Physicians Desk Reference 56th ed p. 2699 (2002)
Prazosin ... is a very potent and selective alpha 1-adrenergic antagonist. ... Interestingly, the drug also is a relatively potent inhibitor of cyclic nucleotide phosphodiesterases...
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 246
LOOKING FOR A SUPPLIER?
